Coherus Oncology Inc (CHRS)

Sep 10, 2025

Coherus BioSciences at H.C. Wainwright: Strategic Shift to Immuno-Oncology - Investing.com

Sep 10, 2025

Sep 10, 2025

Coherus BioSciences at H.C. Wainwright: Strategic Shift to Immuno-Oncology By Investing.com - Investing.com Canada

Sep 10, 2025

Sep 09, 2025

Maxim Group Upgrades Coherus Oncology (NASDAQ:CHRS) to "Buy" - MarketBeat

Sep 09, 2025

Sep 09, 2025

Coherus BioSciences at Baird Conference: Oncology Focus Amid Asset Sales - Investing.com

Sep 09, 2025

Sep 08, 2025

Coherus Biosciences Regains Nasdaq Compliance - TipRanks

Sep 08, 2025

Sep 08, 2025

Coherus Oncology regains Nasdaq compliance after meeting minimum bid price - Investing.com

Sep 08, 2025

Sep 06, 2025

Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat

Sep 06, 2025

Sep 04, 2025

Maxim Group upgrades Coherus Biosciences stock to Buy on oncology pivot By Investing.com - Investing.com South Africa

Sep 04, 2025

Sep 04, 2025

Maxim Group upgrades Coherus Biosciences stock to Buy on oncology pivot - Investing.com Canada

Sep 04, 2025

Sep 04, 2025

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga

Sep 04, 2025

Sep 04, 2025

Coherus Oncology (CHRS) Receives Upgrade from Maxim Group | CHRS Stock News - GuruFocus

Sep 04, 2025

Sep 04, 2025

Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4 - AInvest

Sep 04, 2025

Sep 03, 2025

RSI Reset May Fuel Rebound in Coherus BioSciences Inc.July 2025 Sector Moves & Technical Pattern Recognition Alerts - beatles.ru

Sep 03, 2025

Sep 03, 2025

Coherus Oncology to Participate in Upcoming Investor Conferences - The Manila Times

Sep 03, 2025

Sep 03, 2025

Biotech Leader Coherus Oncology Sets Major Conference Schedule: Baird, Wainwright, and UBS Events - Stock Titan

Sep 03, 2025

Aug 30, 2025

Backtesting results for Coherus BioSciences Inc. trading strategiesJuly 2025 Trends & Real-Time Market Sentiment Alerts - Newser

Aug 30, 2025

Aug 30, 2025

Can machine learning forecast Coherus BioSciences Inc. recoveryTrade Analysis Summary & Safe Capital Allocation Plans - Newser

Aug 30, 2025

Aug 29, 2025

Relative strength of Coherus BioSciences Inc. in sector analysisMarket Movement Recap & Daily Profit Focused Stock Screening - Newser

Aug 29, 2025

Aug 28, 2025

Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat

Aug 28, 2025

Aug 25, 2025

Coherus Oncology: On The Shaping Up (NASDAQ:CHRS) - Seeking Alpha

Aug 25, 2025

Aug 22, 2025

Penny Stocks to Watch: Lantronix and Coherus Oncology Among Top Picks - AInvest

Aug 22, 2025

Aug 18, 2025

Lobbying Update: $125,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative

Aug 18, 2025

Aug 15, 2025

TD Cowen Maintains Coherus Oncology(CHRS.US) With Buy Rating - 富途牛牛

Aug 15, 2025

Aug 12, 2025

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 12, 2025

Aug 11, 2025

Coherus Oncology’s Earnings Call Highlights Growth and Challenges - TipRanks

Aug 11, 2025

Aug 10, 2025

Analysts' Revenue Estimates For Coherus Oncology, Inc. (NASDAQ:CHRS) Are Surging Higher - 富途牛牛

Aug 10, 2025

Aug 10, 2025

Coherus Oncology's (CHRS) Strategic Reinvention: A High-Conviction Biotech Play for the Long Term - AInvest

Aug 10, 2025

Aug 10, 2025

Industry Analysts Just Upgraded Their Coherus Oncology, Inc. (NASDAQ:CHRS) Revenue Forecasts By 21% - simplywall.st

Aug 10, 2025

Aug 10, 2025

Need To Know: Analysts Are Much More Bullish On Coherus Oncology, Inc. (NASDAQ:CHRS) Revenues - Yahoo Finance

Aug 10, 2025

Aug 08, 2025

Coherus Oncology 2025 Q2 Earnings Strong Turnaround with 2404.5% Net Income Surge - AInvest

Aug 08, 2025

Aug 08, 2025

Coherus Oncology shares rise 4.07% premarket after Q2 revenue up 36%. - AInvest

Aug 08, 2025

Aug 08, 2025

Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips - Investing.com

Aug 08, 2025

Aug 08, 2025

Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa

Aug 08, 2025

Aug 08, 2025

Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Aug 08, 2025

Aug 08, 2025

Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

Aug 08, 2025

Aug 08, 2025

Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com

Aug 08, 2025

Aug 08, 2025

Coherus Oncology Reports Strong Q2 2025 Growth - TipRanks

Aug 08, 2025

Aug 08, 2025

Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 08, 2025

Aug 07, 2025

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - 富途牛牛

Aug 07, 2025

Aug 07, 2025

Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 07, 2025

Aug 07, 2025

Coherus Oncology: Q2 Earnings Snapshot - San Antonio Express-News

Aug 07, 2025

Aug 07, 2025

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times

Aug 07, 2025

Aug 07, 2025

Coherus Oncology Q2 2025: LOQTORZI revenue up 36% to $10.0mln. - AInvest

Aug 07, 2025

Aug 07, 2025

Coherus Oncology Reports Second Quarter 2025 Financial Results a - GuruFocus

Aug 07, 2025

Aug 07, 2025

Coherus Oncology Reports 36% Increase in LOQTORZI Net Revenue for Q2 2025 and Updates on Pipeline Progress - Quiver Quantitative

Aug 07, 2025

Aug 06, 2025

Insights Ahead: Coherus BioSciences's Quarterly Earnings - 富途牛牛

Aug 06, 2025

Aug 06, 2025

Coherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by institutional shareholders who own 54% of the company - Yahoo Finance

Aug 06, 2025